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TheburdenofliverdiseaseinEgyptisexceptionallyhighduetothehighestprevalenceofhepatitisCvirus(HCV)resultinginrising
rates of hepatocellular carcinoma (HCC). The aim of the current study was to determine the isoﬂavones in soy and to evaluate the
protective role of soy against CCl4-induced liver damage in rats. Four experimental groups were treated for 8 weeks and included
the control group, soy-supplemented diet (20%w/w) group, the group treated orally with CCl4 (100mg/kg bw) twice a week,
and the group fed soy-supplemented diet and treated with CCl4. Blood and liver tissue samples were collected for biochemical
analyses and histological examination. The results indicated that protein content was 45.8% and the total isoﬂavones recorded
167.3mg/100g soy. Treatment with CCl4 resulted in a signiﬁcant biochemical changes in serum liver tissue accompanied with
severe oxidative stress and histological changes. Supplementation with soy succeeded to restore the elevation of liver enzymes
activities and improved serum biochemical parameters. Moreover, soy supplementation improved the antioxidant enzymes,
decreased lipid peroxidation, and improved the histological picture of the liver tissue. It could be concluded that soy-protein-
enriched isoﬂavones may be a promising agent against liver diseases.
1.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer in the world with an estimated 473,000 new cases
annually [1]. Most patients survive less than 1 year after
diagnosis. In Egypt, the annual prevalence of HCC has
increased signiﬁcantly during the past decade [2]. HCC was
reported to account for about 4.7% of chronic liver disease
(CLD) patients where its epidemiology is characterized by
marked demographic and geographic variations [3]. The
cancer is more common in men with a male: female ratio
exceeding three in high incidence areas.
Liver is subjected to a number of malignant and benign
tumors.Therearethreecommontumorsoftheliver,heman-
giomas, adenomas, and focal nodular hyperplasias. Etiology
of these benign tumors are either congenital or due to
oral contraceptive intake. There is no evidence that any
of these benign lesions progress to malignant tumors [4].
Malignanttumorsincludehepatocellularcarcinoma,cholan-
giocarcinoma,hepatoblastoma,andangiosarcoma.Themost
commonandimportantprimarymalignanttumorishepato-
cellularcarcinoma.Thistumorisoneofthemajormalignant
diseases in the world today. It occurs most frequently in
Asia and sub-Saharan Africa. Cholangiocarcinoma, hepa-
toblastoma, and angiosarcoma are less common but still
important malignant tumors. Metastatic spread of tumors
from elsewhere in the body to the liver is frequent [5].
T h ee t i o l o g yo fH C Cs e e m st ob em u l t i f a c t o r i a l ,a n ds e v -
eral events seem to be necessary for malignant transforma-
tiontooccur.Largegeographicdiﬀerencesintheincidenceof2 ISRN Pharmacology
HCC suggest that environmental factors often contribute to
its development. One common factor is the association with
chronic liver disease, most frequently cirrhosis. Cirrhosis is
seen in about 70–80% of HCC and it has been considered
as a preneoplastic condition. The incidence of HCC varies
depending on the type and etiology of associated cirrhosis
[6].
Soybeans and soy products, which are relatively enriched
in isoﬂavones, are of particular interest due to the fact that
they make up a signiﬁcant dietary protein source in some
areas of the world [7]. Moreover, soy is rich in phenols which
have been reported to exhibit antioxidant activity [8]. Soy
isoﬂavones have been reported to decrease LDL oxidation
both in vitro and in vivo [9]. Dietary ﬂavonoids from a
variety of fruits, vegetables, and beverages have also been
shown to be potent inducers of this enzyme [10, 11]. Soy
phytochemicals can modulate both phase I and II enzymes
in the xenobiotic metabolizing system [12–15]. In vivo and
in vitro experiments have demonstrated that soy and soy
phytochemicals speciﬁcally induce QR activity [16–18]. The
aim of the current study was to evaluate the protective eﬀect
of soy against CCl4-induced liver damage in rats.
2.MaterialsandMethods
2.1. Chemicals and Kits. Carbon tetrachloride (CCl4)w a s
obtained from Morgan Chemical Co. (Cairo, Egypt). Trans-
aminase (ALT and AST) kits were purchased from Spectrum
Diagnostics (Cairo, Egypt). Alpha fetoprotein (AFP) was
purchased from Immunospec (CA, USA). Total protein,
albumin, Cholesterol, triglycerides, superoxide dismutase,
glutathione peroxidase, and lipid peroxidase kits were pur-
chased from Biodiagnostic Co. (Giza, Egypt).
2.2. Plant Materials. Soy bean (Glycine max) was purchased
from the Crop Institute, Agricultural Research Center, Giza,
Egypt in the season 2010.
2.3. Extraction and Determination of Soy Protein and
Isoﬂavones. Soy samples were ground to a ﬁne powder to
pass through a 60-mesh sieve and the soy ﬂour was used
for the determination of protein and isoﬂavones. Crude
protein was determined according to the method described
by AOAC [19]. The soy ﬂour was extracted by methanol
80% using a magnetic stirrer and the extract was used for
the determination of daidzin, genistein, genistin, daidzein
by HPLC according to the method described by Duke et
al. [20]. The isoﬂavones were detected using a UV detector
(Water 486) and online monitoring was done at 260nm.
The data were integrated and recorded using a Millennium
chromatography manger software 2010 (Water Milford MA
O1757).
2.4. Experimental Animals. Three-month old Sprague-Daw-
ley male rats (100–120g, purchased from animal house
colony, Giza, Egypt) were maintained on standard lab diet
(protein: 160.4; fat: 36.3; ﬁber: 41g/kg and metabolizable
energy 12.08MJ) purchased from Meladco Feed Co. (Aubor
City, Cairo, Egypt). Animals were housed in a room free
from any source of chemical contamination, artiﬁcially
illuminated and thermally controlled, at the Animal House
Lab., National Research Centre, Dokki, Cairo, Egypt. After
an acclimatization period of one week, the animals were
dividedintofourgroups(10rats/group)andhousedinﬁlter-
top polycarbonate cages. All animals received human care in
compliance with the guidelines of the Animal Care and Use
Committee of the National Research Center, Dokki, Cairo,
Egypt.
2.5. Experimental Design. Animals within diﬀerent treat-
ment groups received their respective treatment for 8 weeks
as follows: group (1), untreated control; group (2), fed soy
supplemented diet (20% w/w); group (3), treated orally with
CCl4 (100mg/kgbw)twiceaweekfor8weeksandgroup(4),
treated orally with CCl4 and fed soy-supplemented diet. At
theendofthetreatmentperiod(i.e.,day57),allanimalswere
beingfastedfor12hrsandbloodsampleswerecollectedfrom
theretroorbitalvenousplexusunderdiethyletheranesthesia.
Sera were separated using cooling centrifugation and stored
at −20◦C until analysis. The following serum biochemical
analyses were carried out: ALT and AST [21], total protein
[22], albumin [23], cholesterol [24], triglycerides [25], and
alphafetoprotein[26].Afterbloodsampleswerecollected,all
animals were killed and sample of liver tissues of each animal
was dissected, weighed, and homogenized in phosphate
buﬀer (pH 7.4) to give 20% w/v homogenate [27]. This
homogenate was centrifuged at 11500×ga n d4 ◦Cf o r1 0m i n
and the supernatant was stored at −70◦C until analysis.
Lipid peroxide (LP) was estimated by measuring the formed
malondialdehyde (MDA) using thiobarbituric acid reactive
substances method according to the spectrophotometric
method of Buege and Aust [28] and Ruiz-Larrea et al. [29].
The level of lipid peroxide was expressed as nmol MDA per
gram tissue. Hepatic glutathione peroxidase (GPX) activity
was determined by a spectrophotometric method, using
reduced glutathione and cumene hydroperoxide as substrate
and 20μL diluted liver homogenate, according to the modi-
ﬁedmethodofPagliaandValentine[30].Hepaticsuperoxide
dismutase (SOD) activity was assayed spectrophometrically
by the red formazan dye reduction procedure [31] using
50μL diluted liver homogenate. The speciﬁc activity of he-
patic glutathione peroxidase and superoxide dismutase was
expressed as unit/mg liver protein.
Other samples of the liver from all animals within
diﬀerent treatment groups were excised and ﬁxed in 10%
neutral formalin followed by dehydration in ascending
grades of alcohol, clearing in xylene and embedding in
paraﬃn wax. Liver sections (5μm thickness) were stained
with hematoxylin and eosin (H&E) for the histological
examination [32].
2.6. Statistical Analysis. All data were statistically analyzed
by analysis of variance (ANOVA) using the General Linear
Model Procedure of the Statistical Analysis System [33]. The
signiﬁcance of the diﬀerences among treatment groups was
determined by Waller-Duncan k-ratio [34]. All statements of
signiﬁcance were based on probability of P ≤ 0.05.ISRN Pharmacology 3
Table 1: The eﬀect of soy supplementation on diﬀerent treatments on the biochemical serum parameters in rats treated with CCl4.
Parameters Groups
Control Soy CCl4 CCl4 +S o y
ALT (U/mL) 176.88 ±3.54a 173.88 ±4.88a 264.33 ±7.43b 174.25 ±6.98a
AST (U/mL) 65.25 ±3.8a 63.88 ±5.04a 263.63 ±20.2c 63.75 ±3.95a
Albumin (g/dL) 3.64 ±0.09a 3.95 ±0.23a 1.43 ±0.12b 2.98 ±0.26c
Total protein (g/dL) 9.54 ±0.66a 9.32 ±0.7a 5.94 ±0.2b 8.78 ±0.58a
Cholesterol (mg/dL) 62.5 ±4.54a 54.75 ±3.03b 103 ±4.53c 67.5 ±6.07a
Triglycerides (mg/dL) 63.15 ±4.04a 56.71 ±6.23b 117.83 ±1.67c 107 ±6.51d
AFP (IU/mL) 10.04 ±2.42a 6.39 ±0.73b 15.71 ± 1.07c 7.16 ±0.80d
Within each row, means superscript with diﬀerent letters are signiﬁcantly diﬀerent (P ≥ 0.05).
Table 2: The eﬀect of soy supplementation on oxidative stress markers in rat liver treated with CCl4.
Parameters Groups
Control Soy CCl4 CCl4 +S o y
GPX (U/g tissue) 2512.00 ±53.59a 2939.78 ±521.99b 949.10 ±29.39c 2390.68 ±561.57d
SOD (U/g tissue) 1289.63 ±92.3a 4102.94 ±191.76b 834.44 ±48.56c 3425.42 ±205.44d
MDA (nmol/g tissue) 48.48 ±0.58a 41.52 ±5.89b 139.01 ±9.43c 58.27 ±2.22d
Within each row, means superscript with diﬀerent letters are signiﬁcantly diﬀerent (P ≥ 0.05).
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Figure 1: Isoﬂavones concentration in soy ﬂour extract determined
by HPLC (means ± SE).
3. Results
The results of crude protein indicated that crude pro-
tein in soy was high and recorded 45.8% based on dry
matter contents and the total isoﬂavones content recorded
167.3mg/100g soy (Figure 1).
The results of the current study revealed that treatment
with CCl4 resulted in a signiﬁcant increase in ALT and
AST activities, AFP and cholesterol level accompanied
with a signiﬁcant decrease in albumin, total protein, and
triglycerides (Table 1). Animals fed soy-supplemented diet
showed a signiﬁcant decrease in AFP, cholesterol, and tri-
glycerides however; ALT and AST activities and albumin
and total protein were comparable to the control. ALT,
AST, total protein, and cholesterol in animals treated with
CCl4 and fed soy-supplemented diet were comparable to the
control however; a signiﬁcant improvement in albumin and
triglycerides was observed although this treatment did not
normalize them.
The current results revealed that treatment with CCl4
resulted in a severe stress in liver as indicated by the sig-
nificant increase in MDA and the signiﬁcant decrease of
GPX and SOD in liver tissue (Table 2). Animals fed soy-
supplemented diet showed a signiﬁcant decrease in MDA
accompanied with a signiﬁcant increase in GPX and
SOD. However, animals treated with CCl4 and fed soy-
supplemented diet showed a signiﬁcant improvement in the
oxidative stress marker as well as the antioxidant enzymes
activity although these values were still diﬀerent signiﬁcantly
than the control group.
The biochemical analyses were further conﬁrmed by the
histological examination of the liver section. The results
indicated that liver tissue in the control group showed nor-
mal central vein and hepatocytes (Figure 2(a)). Animal fed
soy-supplemented diet also showed normal central vein and
hepatocytes (Figure 2(b)). The liver section in the animals
treated with CCl4 showed an increase in ﬁbrous tissues
and inﬂammatory cells around the congested blood vessel;
moreover, a marked hepatocellular fatty degeneration was
also seen (Figure 2(c)). The hepatocytes of same group were
observedwithlargefattydropletsandnuclearpleomorphism
(Figure 2(d)). The liver of animals treated with CCl4 plus
soy showed marked improvement in most of hepatocytes
and prominent decrease in connective tissue (Figure 2(e))
accompanied with a marked improvement in hepatocytes
and portal vein area (Figure 2(f)).
4. Discussion
The current study revealed that soy is enriched in protein
and isoﬂavones which were found at high concentrations.4 ISRN Pharmacology
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Figure 2: A photomicrograph in liver section of (a) control rat showing the normal central vein and the hepatocytes, (b) rat fed soy-
supplemented diet showing the central vein and the hepatocytes, (c) rat treated with CCl4 showing increase in ﬁbrous tissues and
inﬂammatory cells around the congested blood vessel. Marked hepatocellular fatty degeneration also seen, (d) rat treated with CCl4 showing
hepatocytes with large fatty droplets and nuclear pleomorphism, (e) rat treated with CCl4 and fed soy supplemented diet showing marked
improvement in most of hepatocytes and prominent decrease in connective tissues, and (f) rat treated with CCl4 and fed soy supplemented
diet showing marked improvement in hepatocytes and in the portal vein area.
Similar to these results, Simmen et al. [35] reported that soy
contained high protein content. Moreover, King and Bignell
[36], Hou et al. [37], and Duke et al. [20] reported that soy
contained a high content of isoﬂavones as determined by
HPLC. The isoﬂavones genistin and daidzin constitute 99%
of the total isoﬂavones [38].
In the current study we evaluated the protective role of
soy against CCl4-induced liver damage in rats. The selected
doses of CCl4 and soy were literature based [39, 40]. It
is well known that CCl4 is one of the most extensively
studied hepatotoxins. The mechanism by which CCl4 causes
hepatotoxicity is well documented in a series of reports.ISRN Pharmacology 5
The hepatotoxicity of CCl4 undergoes two phases, the ﬁrst
results from its metabolic conversion to free radical product
CCl
−
3 by Cyt P-450 [41]. Once CCl
−
3 has been formed it
reacts very rapidly with O2 to produce CCl3OO−,am u c h
more reactive radical than CCl
−
3 [42] .T h e s ef r e er a d i c a l s
attack microsomal lipids leading to its peroxidation and
also covalently bind to microsomal lipids and proteins. This
results in the generation of reactive oxygen species (ROS),
which includes the superoxide anion O2,H 2O2 and the
hydroxyl radical.
In the current study, CCl4 caused signiﬁcant changes in
serum biochemical parameters typical to those reported in
the literature [43, 44]. The liver is considered to be the prin-
cipal target organ for CCl4 and the activity of transaminases
are sensitive indicators of acute hepatic necrosis [45, 46].
The elevated levels of ALT, AST, triglycerides, and cholesterol
reported herein indicated severe hepatic parenchymal cells
injury [47–49], whereas the decrease in total protein and
albumin indicated liver necrosis and/or kidney dysfunction
[48]. MDA, an end product of lipid peroxidation, is widely
used as a marker of lipid peroxidation. It is well documented
that CCl4 enhanced lipid peroxidation [44, 48, 50] that is an
indication of free radical mediated toxicity.
Free radicals are known to attack the highly unsaturated
fatty acids of the cell membrane and induce lipid peroxida-
tion that is considered a key process in many pathological
events induced by oxidative stress [51]. In the present study,
MDA was found to be signiﬁcantly higher in the animals
treated with CCl4 suggesting a signiﬁcant eﬀect on lipid
peroxidation and supporting the earlier ﬁndings [52, 53].
Alteration in the hepatic antioxidant status may be a
manifestation of oxidative stress caused by CCl4 and their
metabolites. Both GPX and SOD are considered enzymatic
free radical scavengers in cells. In the present study, GPX and
SOD were found to decline signiﬁcantly in rats treated with
CCl4. It is well known that SOD plays an important role in
theeliminationofROSderivedfromtheperoxidativeprocess
in liver tissues [50]. Moreover, SOD removes superoxide by
converting it to H2O2, which can be rapidly converted to
water by CAT [54]. Taken together, the increased level of
MDAandthedecreasedactivityofantioxidantenzymesGPX
and SOD may be attributed to free radical formation which
initiates chain reactions of direct and indirect bond forma-
tion with cellular molecules (nucleic acids, proteins, lipids,
and carbohydrates) impairing crucial cellular processes that
may ultimately culminate.
In the current study, the elevated serum level of AFP in
the animals treated with CCl4 indicated that it is a potent
hepatocarcinogen, enhances reactive oxygen species (ROS)
formation, and causes oxidative DNA damage, which may
play a role in its carcinogenicity [44, 48, 55, 56]. Therefore,
the current study aﬃrmed that CCl4 can induce hepatotoxi-
city and degeneration in liver cells in rats as indicated by the
elevation of AFP level in serum. Similarly, Engelhardt et al.
[57] reported that AFP was much higher after the exposure
to CCl4 for 3-4 days.
The biochemical study was further conﬁrmed by the
histopathological examination of the liver tissue. The liver
section in CCl4-treated group showed an increase in ﬁbrous
tissues and inﬂammatory cells around the congested blood
vessel and a marked hepatocellular fatty degeneration. The
hepatocytes of same group were observed with large fatty
droplets and nuclear pleomorphism. These histological
changes were similar to those reported earlier [44, 58].
Animals fed soy-supplemented diet showed a signiﬁcant im-
provement in all the biochemical parameters tested and the
histological picture of the liver. Possible explanation for the
diﬀerential eﬀects of soy on the activities of AST and ALT
in plasma is that isoﬂavones and soy protein may inhibit the
liver damage induced by CCl4.
On the other hand, supplementation of the diet with
soy protein signiﬁcantly lowered plasma cholesterol and
t r i g l y c e r i d e sl e v e l sc a u s e db yC C l 4. It is indicated recently
that soy protein intake decreased the hepatic lipid depots of
triacylglycerols and cholesterol and decreased the concentra-
tions of lipid peroxides [59]. The mechanism by which soy
protein decreases serum lipids is not yet fully established.
A possible mechanism of this decrease is the enhancement
of bile acid excretion, by which soy protein acts as dietary
ﬁber to promote bile acid excretion and increase the rate of
cholesterol resynthesis in the liver [60].
Previous report has shown that soy protein may improve
hyperlipidemia due to its eﬀects on the transcription factors,
called sterol regulatory element binding proteins, which are
important in the regulation of enzymes involved in lipid
metabolism in vivo [61]. Moreover, Tovar et al. [62]f o u n d
that soy protein lowered sterol regulatory element binding
protein-1 expression in adipocytes, which also helped pre-
vent the development of hepatic lipotoxicity.
AFP was higher in animals treated with CCl4. This is
likely related to the progression of these agents in liver cir-
rhosis [63]. Soy ingestion signiﬁcantly lowered AFP levels in
the serum of rats. One of the mechanisms for lowering AFP
level may have been the anti-inﬂammatory properties of soy.
Previous studies have indicated that the isoﬂavones in soy
may regulate the inﬂammatory response and immune func-
tion [64, 65]. Moreover, genistein and secoisolariciresinol
have anticancer properties on MCF-7 and BT20 in vitro [66]
and have been suggested as the most potent inhibitors of
cancer cell growth [67].
In the current study, soy supplementation resulted in a
signiﬁcant decrease in lipid peroxidation measured as MDA
concentration in liver. This decrease was accompanied with
a signiﬁcant increase in GPX and SOD activity. Moreover,
diet supplemented with soy succeeded to induce a signiﬁcant
improvement in the oxidative stress markers and antioxidant
status of the liver tissue in rats treated with CCl4. These
results suggested that soy protein may prevent oxidative
damage in the liver by lowering plasma-free fatty acids and
decreasing CYP2E1 expression. Similar observations were
reported recently by Yang et al. [59]. The histopathological
study of liver conﬁrmed these ﬁndings. The liver section of
the animals treated withCCl4 and fed soy-supplemented diet
showed marked improvement in hepatocytes and in the
portal vein area. According to Lila and Raskin [68], the
antioxidative eﬀects of several plant compounds have a po-
tentiating eﬀect of other compounds found in plants. A
mixture of compounds rather than a single compound may6 ISRN Pharmacology
be the key to full antioxidant potency. In this concern,
soy contains other bioactive phytochemicals in addition to
isoﬂavones [69]. Consequently, the antioxidative eﬀects of
soy reported in the current study may be due to several
compounds present in soy.
5. Conclusion
The current study revealed that CCl4 induced severe hepat-
otoxicity typical to those reported in the literature. Supple-
mentation with soy succeeded to protect the liver from the
toxic eﬀects and the oxidative stress of CCl4. These eﬀects
may be due to the antioxidant activity, the anticancer eﬀect,
and the enhancement of immune response of soy compo-
nents since it increased the antioxidant capacity of the body
and reduced the oxidative stress and tumor markers. The
current results concluded that soy contained a combination
of active compounds that may be more eﬃcacious and safer
as chemopreventive agents than individual compounds.
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